Bank of America Corp DE raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 362,952 shares of the specialty pharmaceutical company’s stock after buying an additional 35,069 shares during the period. Bank of America Corp DE’s holdings in Supernus Pharmaceuticals were worth $11,361,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock valued at $209,595,000 after buying an additional 6,692,025 shares during the period. AXA acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $6,519,000. Vanguard Group Inc. boosted its stake in shares of Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock valued at $78,762,000 after buying an additional 156,094 shares during the period. Royce & Associates LP acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $4,069,000. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Supernus Pharmaceuticals by 1,265.5% in the first quarter. BNP Paribas Arbitrage SA now owns 138,760 shares of the specialty pharmaceutical company’s stock valued at $4,343,000 after buying an additional 128,598 shares during the period. 90.95% of the stock is owned by institutional investors and hedge funds.
Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 43.05 on Wednesday. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $44.95. The company’s 50 day moving average price is $41.41 and its 200 day moving average price is $32.21. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of 23.16 and a beta of 1.34.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.22 by $0.03. The company had revenue of $57.58 million during the quarter, compared to analyst estimates of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. On average, analysts expect that Supernus Pharmaceuticals, Inc. will post $1.01 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://stocknewstimes.com/2017/07/19/supernus-pharmaceuticals-inc-supn-shares-bought-by-bank-of-america-corp-de.html.
SUPN has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $31.00 target price on shares of Supernus Pharmaceuticals in a research report on Friday, April 7th. Stifel Nicolaus raised their target price on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, April 3rd. Jefferies Group LLC set a $35.00 target price on Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a report on Thursday, July 13th. Finally, Cowen and Company increased their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $46.14.
In related news, CFO Gregory S. Patrick sold 54,000 shares of the company’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $32.37, for a total value of $1,747,980.00. Following the completion of the transaction, the chief financial officer now directly owns 54,221 shares of the company’s stock, valued at approximately $1,755,133.77. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the company’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $34.90, for a total transaction of $191,950.00. Following the completion of the transaction, the vice president now directly owns 43,887 shares of the company’s stock, valued at $1,531,656.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,097 shares of company stock valued at $3,095,503. Company insiders own 6.70% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
